With one of the best, most experienced and cohesive investment teams in the REIT sector, Ventas is the premier capital partner to leading care providers, developers, research and medical institutions, innovators and other healthcare providers, with a well-earned reputation for using creativity and insight to execute deals that others cannot.
External growth is a core competency at Ventas. We’ve delivered more than $36 billion of accretive investments with superior risk adjusted returns in the past 20 years through a best-in-class investment culture, rigor and process, built on our dedicated team’s deep industry knowledge and diverse expertise across the critical areas of underwriting, finance, investment, banking, development and operations.
Partnerships with Industry Leaders Provide Proprietary Growth
Ventas aligns with superior operators and developers to invest in their long-term growth alongside our own. We have a proven track record of investing in and promoting long-term and growing relationships with partners across our portfolio who bring scale, skill and access to growth opportunities.
Proven Investment Approach
As a disciplined investor, Ventas has a clear set of capital allocation priorities and looks for accretive investments in advantaged properties that will complement our diversified portfolio. We evaluate each opportunity across a wide variety of risk-adjusted measures and invest in high-performing assets and partners who can deliver strong cash flows year after year.
Ventas maintains a balanced investment strategy that has produced significant cash flow, accretion and value creation:
Responsible Development and Redevelopment
Ventas is committed to environmentally and socially responsible development and redevelopment. In collaboration with our partners, our development/redevelopment projects typically pursue LEED® certification. Year-to-date4, we have spent more than $15 million on sustainability projects, and are aiming to achieve LEED Silver certification or higher on 100 percent of our $1.5 billion Research & Innovation development pipeline.
1. Pro forma for remaining spend on ongoing developments and the $1.5B development pipeline.
2. Includes stable and lease up assets in addition to expected remaining spend on in-progress developments, at the Company’s share.
3. Represents growth in Ardent annual revenues since Ventas 2016 property acquisition.
4. Data correct as of Q3 2019 filings, press release, supplemental and earnings conference call dated 10/25/2019.